These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 28898054

  • 1. Synthesis, Radiolabeling, and Characterization of Plasma Protein-Binding Ligands: Potential Tools for Modulation of the Pharmacokinetic Properties of (Radio)Pharmaceuticals.
    Müller C, Farkas R, Borgna F, Schmid RM, Benešová M, Schibli R.
    Bioconjug Chem; 2017 Sep 20; 28(9):2372-2383. PubMed ID: 28898054
    [Abstract] [Full Text] [Related]

  • 2. In Vivo Labeling of Plasma Proteins for Imaging of Enhanced Vascular Permeability in the Lungs.
    Schniering J, Borgna F, Siwowska K, Benešová M, Cohrs S, Hasler R, van der Meulen NP, Maurer B, Schibli R, Müller C.
    Mol Pharm; 2018 Nov 05; 15(11):4995-5004. PubMed ID: 30265552
    [Abstract] [Full Text] [Related]

  • 3. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
    Benešová M, Umbricht CA, Schibli R, Müller C.
    Mol Pharm; 2018 Mar 05; 15(3):934-946. PubMed ID: 29400475
    [Abstract] [Full Text] [Related]

  • 4. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
    Deberle LM, Benešová M, Umbricht CA, Borgna F, Büchler M, Zhernosekov K, Schibli R, Müller C.
    Theranostics; 2020 Mar 05; 10(4):1678-1693. PubMed ID: 32042329
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Design and Evaluation of Novel Albumin-Binding Folate Radioconjugates: Systematic Approach of Varying the Linker Entities.
    Benešová M, Guzik P, Deberle LM, Busslinger SD, Landolt T, Schibli R, Müller C.
    Mol Pharm; 2022 Mar 07; 19(3):963-973. PubMed ID: 35192367
    [Abstract] [Full Text] [Related]

  • 9. Preclinical Comparison of Albumin-Binding Radiofolates: Impact of Linker Entities on the in Vitro and in Vivo Properties.
    Siwowska K, Haller S, Bortoli F, Benešová M, Groehn V, Bernhardt P, Schibli R, Müller C.
    Mol Pharm; 2017 Feb 06; 14(2):523-532. PubMed ID: 28094532
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
    Yordanov AT, Hens M, Pegram C, Bigner DD, Zalutsky MR.
    Nucl Med Biol; 2007 Feb 06; 34(2):173-83. PubMed ID: 17307125
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Development and Evaluation of DOTA-FAPI-Maleimide as a Novel Radiotracer for Tumor Theranostic with Extended Circulation.
    Feng L, Hu W, Zeng X, Wei Z, Long Y, Li M, Sun S, Guo Z, Lan X, Zhang X, Zhuang R, Jiang D.
    Mol Pharm; 2024 Sep 02; 21(9):4386-4394. PubMed ID: 39046432
    [Abstract] [Full Text] [Related]

  • 20. Dual Radionuclide Theranostic Pretargeting.
    Keinänen O, Brennan JM, Membreno R, Fung K, Gangangari K, Dayts EJ, Williams CJ, Zeglis BM.
    Mol Pharm; 2019 Oct 07; 16(10):4416-4421. PubMed ID: 31483993
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.